Key facts
- This page summarizes Jason Ehrlich's Form 4 filing for Kodiak Sciences Inc. (KOD).
- 5 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 15 Jun 2021, 19:06.
Jason Ehrlich - 11 Jun 2021 Form 4 Insider Report for Kodiak Sciences Inc. (KOD)
- Reporting relationship
- Chief Medical Officer and Chief Development Officer
- Issuer ticker
- KOD
- Reported as of
- 11 Jun 2021
- Net transaction value
- -$97,208
- SEC form
- 4
- Accepted by SEC
- 15 Jun 2021, 19:06:52 UTC
- Prior SEC filing
- 24 May 2021
- Next SEC filing
- 17 Jun 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ David Peinsipp, Attorney-in-Fact for Jason Ehrlich
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jason Ehrlich filed Form 4 for Kodiak Sciences Inc. (KOD) on 15 Jun 2021.
Change
- Previous filing in this sequence was filed on 24 May 2021.
- Current net transaction value: -$97,208.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
KOD
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +2,900
- Change %
- +4.6%
- Price
- Shares after
- 66,115
- Date
- 11 Jun 2021
- Ownership
- Direct
- Footnotes
- F1, F2
KOD
transaction
Common Stock
Sale
- Transaction value
- $97,208
- Shares
- -1,147
- Change %
- -1.7%
- Price
- $84.75*
- Shares after
- 64,968
- Date
- 15 Jun 2021
- Ownership
- Direct
- Footnotes
- F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
KOD
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +18,450
- Change %
- Price
- $0.000000
- Shares after
- 18,450
- Date
- 11 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 18,450
- Exercise price
- $73.51
- Footnotes
- F4
KOD
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +11,600
- Change %
- Price
- $0.000000
- Shares after
- 11,600
- Date
- 11 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 11,600
- Exercise price
- Footnotes
- F1, F4
KOD
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -2,900
- Change %
- -25%
- Price
- $0.000000
- Shares after
- 8,700
- Date
- 11 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,900
- Exercise price
- Footnotes
- F1, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's common stock.
Footnote F2
Includes 54 shares acquired under the 2018 Employee Stock Purchase Plan on May 31, 2021.
Footnote F3
The sale was made to cover tax withholding obligations in connection with vesting and settlement of 1/4th of the Reporting Person's performance-based RSU granted on December 30, 2019.
Footnote F4
On December 30, 2019 the Reporting Person was awarded a performance-based award. 1/4th of the award vested on June 11, 2021 upon the achievement of certain performance criteria ("Performance Achievement Date"); thereafter, the award will vest in three equal annual installments on each of the first, second, and third anniversaries of the Performance Achievement Date, subject, in each case, to the Reporting Person's status as a Service Provider (as defined in the 2018 Equity Incentive Plan) on each vesting date.
SEC remarks
Chief Medical Officer and Chief Development Officer